(Q59273983)
Statements
A phase Ib, dose-finding study of erlotinib in combination with a fixed dose of pertuzumab in patients with advanced non-small-cell lung cancer (English)
Malcolm Ranson
Susana Cedrés
Mike Brewster
Pablo Martínez
Virginia McNally
Graham Ross
Danny Galdermans